Filtered By:
Condition: Guillain-Barr Syndrome

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 314 results found since Jan 2013.

Acute Occupational and Physical Therapy for COVID-19 Patients: A Retrospective Cohort Study
In March 2020, the World Health Organization (WHO) declared the novel coronavirus strain SARS-CoV2 (the virus causing COVID-19) a global pandemic.24 The severity of illness in those exhibiting symptoms ranges from mild (cough, shortness of breath, fatigue) to severe (acute respiratory distress syndrome (ARDS), thrombosis, stroke, and death).4,11 Patients have also acquired acute polyradiculoneuritis (Guillain Barre syndrome) at a disproportionately high rate, contributing to functional limitations that require specialized and intensive rehabilitation.
Source: Archives of Physical Medicine and Rehabilitation - July 31, 2022 Category: Rehabilitation Authors: Katie Coakley, Laura Friedman, Kaitlyn McLoughlin, Amy Wozniak, Paul Hutchison Tags: Original Research Source Type: research

The Potential for Treg-Enhancing Therapies in Nervous System Pathologies
Clin Exp Immunol. 2022 Aug 30:uxac084. doi: 10.1093/cei/uxac084. Online ahead of print.ABSTRACTWhile inflammation may not be the cause of disease, it is well known that it contributes to disease pathogenesis across a multitude of peripheral and central nervous system disorders. Chronic and overactive inflammation due to an effector T cell-mediated aberrant immune response ultimately leads to tissue damage and neuronal cell death. To counteract peripheral and neuroinflammatory responses, research is being focused on regulatory T cell enhancement as a therapeutic target. Regulatory T cells are an immunosuppressive subpopulat...
Source: Clinical and Developmental Immunology - August 30, 2022 Category: Allergy & Immunology Authors: Katherine E Olson R L Mosley Howard E Gendelman Source Type: research

Neurological Effects of Monkeypox Largely Unknown, Review Finds
Much remains unknown about the long-term neurologic effects of monkeypox. In anarticle published today inJAMA Neurology, researchers from the National Institute of Neurological Disorders and Stroke (NINDS) and colleagues described how reports of complications from other orthopoxviruses, such as smallpox, may offer clues about the neurologic consequences of monkeypox.“Although the COVID-19 pandemic is the worst pandemic in a century, the recent past has seen several major pandemics, including Zika, Ebola, dengue, West Nile, and AIDS,” wrote B. Jeanne Billioux, M.D., of NINDS and colleagues. “A common thread to these p...
Source: Psychiatr News - September 20, 2022 Category: Psychiatry Tags: febrile seizures/encephalopathy headache JAMA Neurology monkeypox neurological problems smallpox transverse myelitis Source Type: research

Active Post-Licensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Am J Epidemiol. 2022 Oct 4:kwac170. doi: 10.1093/aje/kwac170. Online ahead of print.ABSTRACTRecombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster and its complications in older adults. In this prospective, post-licensure Vaccine Safety Datalink (VSD) study using electronic health records, we sequentially monitored a real-world population of adults aged 50 years and older who received care at multiple VSD health systems in the United States to identify potential increased risks of 10 pre-specified prior...
Source: Herpes - October 4, 2022 Category: Infectious Diseases Authors: Jennifer C Nelson Ernesto Ulloa-P érez Onchee Yu Andrea J Cook Michael L Jackson Edward A Belongia Matthew F Daley Rafael Harpaz Elyse O Kharbanda Nicola P Klein Allison L Naleway Hung-Fu Tseng Eric S Weintraub Jonathan Duffy W Katherine Yih Lisa A Jacks Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research

Neurological manifestations of COVID-19: a retrospective observational study based on 1060 patients with a narrative review
CONCLUSION: Our data are coherent with the published literature. Knowledge of these patterns will make clinicians consider COVID-19 infection when unexplained neurological findings are encountered.PMID:36451533 | DOI:10.1177/02841851221138557
Source: Acta Radiologica - December 1, 2022 Category: Radiology Authors: Alberto Negro Mario Tortora Laura Gemini Arturo de Falco Francesco Somma Vincenzo d'Agostino Source Type: research

Neurological Complications and Consequences of the Novel Coronavirus COVID-19 Infection in Elderly and Senile Patients (Literature Review)
AbstractBased on available publications, the article systematizes information about some forms of lesions of the central nervous system (CNS), their pathogenesis and clinical manifestations in the case of COVID-19. The risk factors, mechanisms of development, diagnostic approach, and the age characteristics of patients with neurological complications of COVID-19 are discussed. The specific mechanisms of the neuroinvasiveness and neurovirulence of the SARS-CoV-2 virus, regardless of the age of patients and the presence of risk factors, lead to systemic damage to the endothelium of small-caliber vessels, generalized thrombov...
Source: Advances in Gerontology - December 1, 2022 Category: Geriatrics Source Type: research

Viral diseases of the nervous system-Selected new and old viruses
Nervenarzt. 2023 Mar 21. doi: 10.1007/s00115-023-01452-0. Online ahead of print.ABSTRACTViral diseases of the nervous system are ancient and poliomyelitis was described in Egypt as early as 2000 BC. They can cause a wide range of neurological symptoms, such as meningitis, encephalitis, meningoencephalitis, Guillain-Barré-like syndrome and stroke, often leaving mild to severe residuals. Depending on the pathogen, the symptoms appear quickly within hours, or lead to increasing chronic symptoms within 1 week or months. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was newly identified in January 202...
Source: Herpes - March 21, 2023 Category: Infectious Diseases Authors: Uta Meyding-Lamad é Eva Maria Craemer Source Type: research